1-3 of 3
Elizabeth Wiley
Close
Sort by
Journal Articles

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

Clinical Trials & Observations
Jennifer A. Woyach, Farrukh Awan, Ian W. Flinn, Jesus G. Berdeja, Elizabeth Wiley, Sharmeen Mansoor, Ying Huang, Gerard Lozanski, Paul A. Foster, John C. Byrd
Journal: Blood
Blood (2014) 124 (24): 3553–3560.
https://doi.org/10.1182/blood-2014-08-593269
Published: 2014
Includes: Supplemental data
Journal Articles

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Joseph M. M. Flynn, DO, MPH, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, MPH, Amy J. Johnson, PhD, Kami Maddocks, MD, Elizabeth Wiley, Karen Small, BSN, Eun Kyung Im, MD, Michael R. Grever, MD, Rajat Bannerji, MD, PhD, John C. Byrd, MD, Honghong Zhou, PhD
Journal: Blood
Blood (2013) 122 (21): 871.
https://doi.org/10.1182/blood.V122.21.871.871
Published: 2013
Journal Articles

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Kristie A. Blum, MD, Amy J. Johnson, PhD, Josh Hessler, Elizabeth Wiley, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PhD, John C. Byrd, MD
Journal: Blood
Blood (2010) 116 (21): 1396.
https://doi.org/10.1182/blood.V116.21.1396.1396
Published: 2010